Cineca (European Horizon 2020 Framework Program)
Over the last forty years there has been an increasing number of large cohorts of human samples from research and national healthcare initiatives. Rapid advances in molecular biology technology such as DNA genotyping and sequencing has enabled ever larger cohorts facilitating the study of diseases and their causes.
To maximize the impact of this data for researchers, healthcare, industry, patients and founders, Cineca has assembled a set of expert partners embedded in the communities that generate, analyse, standardize and share genomic data. Cineca aim is to deliver federated analysis solutions across cohorts and international borders thereby accelerating research and improving health care across continents.
Cineca is a project of the European Horizon 2020 Framework Program (Research and Innovative Actions) and ClinicaGeno is a beneficiary in this awarded grant. For more information see www.cineca-project.eu.
Over the last forty years there has been an increasing number of large cohorts of human samples from research and national healthcare initiatives. Rapid advances in molecular biology technology such as DNA genotyping and sequencing has enabled ever larger cohorts facilitating the study of diseases and their causes.
To maximize the impact of this data for researchers, healthcare, industry, patients and founders, Cineca has assembled a set of expert partners embedded in the communities that generate, analyse, standardize and share genomic data. Cineca aim is to deliver federated analysis solutions across cohorts and international borders thereby accelerating research and improving health care across continents.
Cineca is a project of the European Horizon 2020 Framework Program (Research and Innovative Actions) and ClinicaGeno is a beneficiary in this awarded grant. For more information see www.cineca-project.eu.
Valbiome
The success rate of In Vitro Fertilization (IVF) therapy is still disappointing for couples and their caregivers. 33% of the IVFs fail in the first round leading to a total of 58% IVFs that failed after 3 rounds. However, evidence accumulates that disturbances in the vaginal microbiota can be considered as an important and actionable biomarker to predict IVF failure. The Valbiome project is developing an easy-to-use CE-IVD certified test that enables physicians to assess and monitor the vaginal microbial profile to predict in which women IVF failure is highly likely. The second step (outside of the Valbiome grant) is to alter the vaginal microbiome in femals such that IVF therapy can be initiated again.
The test enables clinicians to retrieve their patients results from an online database which is based on ClinicaGeno’s CHUB platform. Data produced by the diagnostic kit can be uploaded to CHUB via a client application where proprietary algorithms for analysis of vaginal microbiota - linked to CHUB - allow for remote analysis of the data. After analysis the data is stored in a database and a report containing the profiling results is generated and provided to the user.
Eurostars is a European program supporting research-performing small and medium enterprises. ClinicaGeno is a beneficiary in this awarded grant coordinated by the main applicant Microbiome Ltd.
The success rate of In Vitro Fertilization (IVF) therapy is still disappointing for couples and their caregivers. 33% of the IVFs fail in the first round leading to a total of 58% IVFs that failed after 3 rounds. However, evidence accumulates that disturbances in the vaginal microbiota can be considered as an important and actionable biomarker to predict IVF failure. The Valbiome project is developing an easy-to-use CE-IVD certified test that enables physicians to assess and monitor the vaginal microbial profile to predict in which women IVF failure is highly likely. The second step (outside of the Valbiome grant) is to alter the vaginal microbiome in femals such that IVF therapy can be initiated again.
The test enables clinicians to retrieve their patients results from an online database which is based on ClinicaGeno’s CHUB platform. Data produced by the diagnostic kit can be uploaded to CHUB via a client application where proprietary algorithms for analysis of vaginal microbiota - linked to CHUB - allow for remote analysis of the data. After analysis the data is stored in a database and a report containing the profiling results is generated and provided to the user.
Eurostars is a European program supporting research-performing small and medium enterprises. ClinicaGeno is a beneficiary in this awarded grant coordinated by the main applicant Microbiome Ltd.
Diagoras
The objective of this project is to develop a point-of-care microbiological diagnostic platform for use in general practitioner offices, dentist practices and hospital emergency rooms. The platform will detect respiratory and oral infections, along with antibiotic resistances within 1 hour, thereby reducing: i) time-to-diagnosis, ii) patient morbidity/mortality and iii) incorrect antibiotic use. Importantly, the device will allow on-site, rapid and accurate prescription of personalized treatment procedures, with significant impact on healthcare costs and the constant increase in antibiotic resistant bacterial pathogens.
This test will include access to an online data storage which is based on ClinicaGeno’s CHUB platform. In addition, ClinicaGeno is responsible for the development of software algorithms for data analysis and interpretation as well as providing clinically meaningful reports to end-users.
Diagoras is a project of the European Horizon 2020 Framework Program (Research and Innovative Actions) and Clinicageno is a beneficiary in this awarded grant.
The objective of this project is to develop a point-of-care microbiological diagnostic platform for use in general practitioner offices, dentist practices and hospital emergency rooms. The platform will detect respiratory and oral infections, along with antibiotic resistances within 1 hour, thereby reducing: i) time-to-diagnosis, ii) patient morbidity/mortality and iii) incorrect antibiotic use. Importantly, the device will allow on-site, rapid and accurate prescription of personalized treatment procedures, with significant impact on healthcare costs and the constant increase in antibiotic resistant bacterial pathogens.
This test will include access to an online data storage which is based on ClinicaGeno’s CHUB platform. In addition, ClinicaGeno is responsible for the development of software algorithms for data analysis and interpretation as well as providing clinically meaningful reports to end-users.
Diagoras is a project of the European Horizon 2020 Framework Program (Research and Innovative Actions) and Clinicageno is a beneficiary in this awarded grant.
Tubatest
Almost 25% of women with Chlamydia-associated subfertility are faced with sub-optimal clinical decision making or triage due to a lack of accurate diagnostic tools. Twin research has shown that up to 40% of the response to Chlamydia trachomatis infection is based the host’s genetic make-up. Ongoing genetic studies have enabled the discovery of first multiple Single Nucleotide Polymorphisms (SNP) and their potential role as subfertility biomarkers. The Tubatest project is developing a diagnostic assay based on host genetic SNP profiling enabling the accurate diagnosis of women with Chlamydia-associated subfertility.
This test will include access to an online database which is based on ClinicaGeno’s CHUB platform. Data produced by the diagnostic kit is uploaded via a client application to CHUB. CHUB initializes an automated analysis of the data, leading to the generation of a diagnostic report containing the profiling results.
Eurostars is a European program supporting research-performing small and medium enterprises. ClinicaGeno is a beneficiary in this awarded grant coordinated by the main applicant TubaScan Ltd.
Almost 25% of women with Chlamydia-associated subfertility are faced with sub-optimal clinical decision making or triage due to a lack of accurate diagnostic tools. Twin research has shown that up to 40% of the response to Chlamydia trachomatis infection is based the host’s genetic make-up. Ongoing genetic studies have enabled the discovery of first multiple Single Nucleotide Polymorphisms (SNP) and their potential role as subfertility biomarkers. The Tubatest project is developing a diagnostic assay based on host genetic SNP profiling enabling the accurate diagnosis of women with Chlamydia-associated subfertility.
This test will include access to an online database which is based on ClinicaGeno’s CHUB platform. Data produced by the diagnostic kit is uploaded via a client application to CHUB. CHUB initializes an automated analysis of the data, leading to the generation of a diagnostic report containing the profiling results.
Eurostars is a European program supporting research-performing small and medium enterprises. ClinicaGeno is a beneficiary in this awarded grant coordinated by the main applicant TubaScan Ltd.
EpiPredict
EpiPredict is a project of the European Horizon 2020 Framework Program (Marie Skłodowska-Curie Actions, Innovative Training Networks). The mission of EpiPredict is to train Early-Stage Researchers (ESRs) to exploit the Epigenetics of complex diseases. The focus is on Tamoxifen-induced resistance in Estrogen Receptor positive breast cancer. Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. Therefore the training program employs a systems medicine approach combining next-generation systematic Epigenetic, gene/protein profiling with innovative gene-specific Epigenetic interference technologies and computational modelling.
The aim is the identification of key Epigenetic changes underlying Tamoxifen induced resistance providing an important step towards diagnostic markers/tools to predict treatment outcomes and monitor drug response.
EpiPredict is a project of the European Horizon 2020 Framework Program (Marie Skłodowska-Curie Actions, Innovative Training Networks) and Clinicageno a partner of the project consortium. For more information see www.epipredict.eu.
EpiPredict is a project of the European Horizon 2020 Framework Program (Marie Skłodowska-Curie Actions, Innovative Training Networks). The mission of EpiPredict is to train Early-Stage Researchers (ESRs) to exploit the Epigenetics of complex diseases. The focus is on Tamoxifen-induced resistance in Estrogen Receptor positive breast cancer. Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. Therefore the training program employs a systems medicine approach combining next-generation systematic Epigenetic, gene/protein profiling with innovative gene-specific Epigenetic interference technologies and computational modelling.
The aim is the identification of key Epigenetic changes underlying Tamoxifen induced resistance providing an important step towards diagnostic markers/tools to predict treatment outcomes and monitor drug response.
EpiPredict is a project of the European Horizon 2020 Framework Program (Marie Skłodowska-Curie Actions, Innovative Training Networks) and Clinicageno a partner of the project consortium. For more information see www.epipredict.eu.